Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308799 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
A Phase 3 study, sponsored by MC2 Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 794
- Enrollment target
NCT03308799: Completed Phase 3 study, sponsored by MC2 Therapeutics.
NCT03308799 is a Phase 3 study that has completed, run by MC2 Therapeutics. The registered enrollment target is 794 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03308799, a Phase 3 study, has completed, sponsored by MC2 Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 794 participants
- Enrollment target
Study Summary
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
Primary Outcome
Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening. The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.
Interventions
- DRUG MC2-01 cream
- DRUG Cal/BDP combination
- DRUG Cream vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 794 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2018-06-08 |
| Phase | Phase 3 |
What the finished NCT03308799 record still lists
NCT03308799 is an interventional study that assigns participants to a tested intervention. The registered 794 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which MC2-01 cream is the first listed.
NCT03308799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03308799 about?
NCT03308799 is a clinical study titled "A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream". This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
What is the current status of trial NCT03308799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 794 participants. The study started on 2017-10-03. Estimated completion is 2018-06-08.
What interventions are being tested in trial NCT03308799?
The interventions under investigation include: MC2-01 cream (DRUG), Cal/BDP combination (DRUG), Cream vehicle (DRUG).
Who is sponsoring clinical trial NCT03308799?
This trial is sponsored by MC2 Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03308799's enrollment target sits among peer trials
794 429th of 2000 higher than 1,572 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI